Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011

Journal of Clinical Microbiology

Volumn 50, Issue 11, 2012, Pages 3435-3442

  Lockhart, Shawn R ^a   Iqbal, Naureen ^a   Cleveland, Angela A ^a   Farley, Monica M ^b,c   Harrison, Lee H ^d   Bolden, Carol B ^a   Baughman, Wendy ^b   Stein, Betsy ^c   Hollick, Rosemary ^d   Park, Benjamin J ^a   Chiller, Tom ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA BRACARENSIS; CANDIDA CATENULATA; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA FERMENTATI; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA METAPSILOSIS; CANDIDA NIVARIENSIS; CANDIDA NORVEGENSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA PARARUGOSA; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDEMIA; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DISEASE SURVEILLANCE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; KLUYVEROMYCES MARXIANUS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; SPECIES DIFFERENCE; SPECIES DISTRIBUTION; UNITED STATES;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; COINFECTION; GEORGIA; HUMANS; MARYLAND; MICROBIAL SENSITIVITY TESTS;

EID: 84867512787     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01283-12     Document Type: Article

References (38)

1. Abi-Said D, et al. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128. (Pubitemid 127774267)
2. Arendrup MC, et al. 2011. National surveillance of fungemia in Denmark (2004 to 2009). J. Clin. Microbiol. 49:325-334.
3. Asmundsdóttir LR, Erlendsdóttir H, Gottfredsson M. 2002. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol. 40:3489-3492. (Pubitemid 34977475)
4. Banerjee SN, et al. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91:86S-89S.
5. Chen S, et al. 2006. Active surveillance for candidemia, Australia. Emerg. Infect. Dis. 12:1508-1516. (Pubitemid 44570891)
6. Cuenca-Estrella M, et al. 2005. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother. 55:194-199. (Pubitemid 40331145)
7. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical Laboratory Standards Institute, Wayne, Pa.
8. Deak E, et al. 2010. Utility of a Luminex-based assay for multiplexed, rapid species identification of Candida isolates from an ongoing candidemia surveillance. Can. J. Microbiol. 56:348-351.
9. Diekema DJ, et al. 2002. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. 40:1298-1302. (Pubitemid 34279892)
10. Hajjeh RA, et al. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527. (Pubitemid 38500790)
11. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. 2009. Excess mortality, length of stay and cost attributable to candidaemia. J. Infect. 59:360-365.
12. Kao AS, et al. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170. (Pubitemid 30265634)
13. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. 2005. Invasive Candida species infections: a 5 year population-based assessment. J. Antimicrob. Chemother. 56:532-537. (Pubitemid 41264132)
14. Lockhart SR, Bolden CB, Iqbal N, Kuykendall RJ. 2011. Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method. J. Clin. Microbiol. 49:4322-4325.
15. Lortholary O, et al. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55:532-538.
16. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study Investigators. 2010. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J. Clin. Microbiol. 48:1270-1275.
17. Morgan J, et al. 2005. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 26:540-547. (Pubitemid 40896144)
18. Nguyen MH, et al. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100: 617-623. (Pubitemid 26243671)
19. Odds FC, et al. 2007. One year prospective survey of Candida bloodstream infections in Scotland. J. Med. Microbiol. 56:1066-1075. (Pubitemid 47262669)
20. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
21. Pfaller MA, et al. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of speciesspecific interpretive criteria. Diagnost. Microbiol. Infect. Dis. 70:330-343.
22. Pfaller MA, et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
23. Pfaller MA, et al. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
24. Pfaller MA, et al. 2011. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. J. Clin. Microbiol. 49:1274-1279.
25. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
26. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. (Pubitemid 46167771)
27. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
28. Pfaller MA, et al. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48:1366-1377.
29. Pfaller MA, et al. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 30:121-129. (Pubitemid 28102867)
30. Pfaller MA, et al. 1999. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33:217-222. (Pubitemid 29142360)
31. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J. Clin. Microbiol. 49:396-399.
32. Poikonen E, et al. 2010. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect. Dis. 10:312. doi:10.1186/1471- 2334-10-312.
33. Sandven P, et al. 2006. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44:1977-1981. (Pubitemid 43902142)
34. St-Germain G, et al. 2008. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can. J. Infect. Dis. Med. Microbiol. 19:55-62. (Pubitemid 351547673)
35. Tortorano AM, et al. 2002. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J. Hosp. Infect. 51:297-304. (Pubitemid 38001880)
36. Trick WE, et al. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35:627-630.
37. Wisplinghoff H, et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. (Pubitemid 39050477)
38. Zimbeck AJ, et al. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54:5042-5047.